Patents-Review.com
ClassID:

21134 ⎘

A61K39/275 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies; Viral antigens Poxviridae, e.g. avipoxvirus

Sub-classes:
Recent Application in this class:
#1
20260139233
2026-05-21

SYNTHETIC CHIMERIC POXVIRUSES

 #2
20260130985
2026-05-14

NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF

 #3
20260069682
2026-03-12

NANOPARTICLE-DERIVED VACCINES AGAINST POXVIRUSES, AND METHODS FOR MAKING AND USING THE SAME

 #4
20260022350
2026-01-22

SYNTHETIC CHIMERIC POXVIRUSES

 #5
20260000644
2026-01-01

POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION

 #6
20250339511
2025-11-06

NUCLEIC ACID VACCINE AGAINST MONKEYPOX VIRUS AND USE THEREOF

 #7
20250319177
2025-10-16

RNA COMPOSITIONS FOR DELIVERY OF MONKEYPOX ANTIGENS AND RELATED METHODS

 #8
20250084384
2025-03-13

CHIMERIC POXVIRUS COMPOSITIONS AND USES THEREOF

 #9
20240382580
2024-11-21

MULTIVALENT VIRAL PARTICLES

 #10
20240269257
2024-08-15

INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION

 #11
20240156782
2024-05-16

POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION

 #12
20240091338
2024-03-21

NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES

 #13
20240043870
2024-02-08

MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY

 #14
20240042037
2024-02-08

REDUCED FOAMING VACCINE COMPOSITIONS

 #15
20240024464
2024-01-25

MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY

 #16
20230390389
2023-12-07

Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines

 #17
20230346910
2023-11-02

Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process

 #18
20230338516
2023-10-26

RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULES

 #19
20230338506
2023-10-26

RESPIRATORY VIRUS IMMUNIZING COMPOSITIONS

 #20
20230270847
2023-08-31

Recombinant Viral Vector, Immunogenic Composition Comprising Same, and Uses

 #21
20230031287
2023-02-02

METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE

 #22
20230025706
2023-01-26

NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS

 #23
20230009041
2023-01-12

MODIFIED IMMUNIZATION VECTORS

 #24
20230002741
2023-01-05

SYNTHETIC CHIMERIC POXVIRUSES

 #25
20220401554
2022-12-22

USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES

 #26
20220401553
2022-12-22

PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS

 #27
20220241421
2022-08-04

REDUCED FOAMING VACCINE COMPOSITIONS

 #28
20220241395
2022-08-04

Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process

 #29
20220218818
2022-07-14

SMALLPOX VACCINE AND STEM CELLS FOR TREATMENT OF DISEASE

 #30
20220118077
2022-04-21

Immunogen for broad-spectrum influenza vaccine and application thereof

 #31
20220072122
2022-03-10

Method for generating recombinant poxviruses

 #32
20220040160
2022-02-10

COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY

 #33
20210324014
2021-10-21

A NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS

 #34
20210206852
2021-07-08

Compositions and methods to enhance the immune system

 #35
20210205442
2021-07-08

Myxoma virus compositions and methods of use

 #36
20210196812
2021-07-01

Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production

 #37
20210169853
2021-06-10

Corroles for treating poxvirus infection

 #38
20210162040
2021-06-03

Triple vaccine against and avian encephalomyelitis virus and fowl pox virus

 #39
20210137885
2021-05-13

Polymorphic forms of ST-246 and methods of preparation

 #40
20210113684
2021-04-22

VECTOR-BASED ATTENUATED POXVIRUS VACCINES

 #41
20210061864
2021-03-04

Oncolytic virus platform to treat cancers with myxoma virus

 #42
20200397890
2020-12-24

Antiviral vaccines with improved cellular immunogenicity

 #43
20200188519
2020-06-18

REDUCED FOAMING VACCINE COMPOSITIONS

 #44
20200188509
2020-06-18

Orf virus-based platform for vaccine delivery

 #45
20200172926
2020-06-04

Modified immunization vectors

 #46
20200108094
2020-04-09

Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process

 #47
20200102544
2020-04-02

Poxvirus-recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same

 #48
20200046830
2020-02-13

NUCLEIC ACID VACCINE COMPOSITION COMPRISING A LIPID FORMULATION, AND METHOD OF INCREASING THE POTENCY OF NUCLEIC ACID VACCINES

 #49
20200009245
2020-01-09

Vector-based attenuated poxvirus vaccines

 #50
20190314492
2019-10-17

Antiviral vaccines with improved cellular immunogenicity

 #51
20190218522
2019-07-18

Chimeric poxvirus compositions and uses thereof

 #52
20190201520
2019-07-04

Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production

 #53
20190183870
2019-06-20

COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY

 #54
20190151451
2019-05-23

Methods of making solid vaccine compositions having reduced foaming

 #55
20190099479
2019-04-04

Recombinant HCMV and RHCMV vectors and uses thereof

 #56
20190000978
2019-01-03

Reduced foaming vaccine compositions

 #57
20180256704
2018-09-13

Novel Prime-Boosting Regimens Involving Immunogenic Polypeptides Encoded by Polynucleotides

 #58
20180251736
2018-09-06

Synthetic chimeric poxviruses

 #59
20180243406
2018-08-30

INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS

 #60
20180243405
2018-08-30

INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS

 #61
20180193437
2018-07-12

Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants

 #62
20180155424
2018-06-07

Compositions and methods to enhance the immune system

 #63
20180085313
2018-03-29

Thermostable vaccines based on ether lipids and native viral envelope proteins

 #64
20180028649
2018-02-01

Synthetic glucopyranosyl lipid adjuvants

 #65
20170326230
2017-11-16

Stable liquid vaccinia virus formulations

 #66
20170275364
2017-09-28

Compositions and methods to enhance the immune system

 #67
20170246280
2017-08-31

Modified immunization vectors

 #68
20170239344
2017-08-24

Antiviral vaccines with improved cellular immunogenicity

 #69
20170224807
2017-08-10

Newcastle disease virus vectored avian vaccines

 #70
20170182155
2017-06-29

Synthetic glucopyranosyl lipid adjuvants

 #71
20170088635
2017-03-30

Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use

 #72
20170044258
2017-02-16

Compositions and methods to enhance the immune system

 #73
20160256554
2016-09-08

Reduced foaming vaccine compositions

 #74
20160256540
2016-09-08

Methods And Compositions For Treatment Of S. Equi Infection

 #75
20160244522
2016-08-25

Compositions and methods to enhance the immune system

 #76
20160114027
2016-04-28

Recombinant HCMV and RHCMV vectors and uses thereof

 #77
20160024156
2016-01-28

Antiviral vaccines with improved cellular immunogenicity

 #78
20150209420
2015-07-30

NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES

 #79
20150191704
2015-07-09

POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME

 #80
20150030623
2015-01-29

Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

 #81
20140322268
2014-10-30

Synthetic glucopyranosyl lipid adjuvants

 #82
20140242115
2014-08-28

Inactivating pathogens with oxidizing agents for vaccine production

 #83
20140199308
2014-07-17

Compositions and methods to enhance the immune system

 #84
20140044752
2014-02-13

Inactivated virus compositions and methods of preparing such compositions

 #85
20130316434
2013-11-28

Animal protein free media for cultivation of cells

 #86
20130295133
2013-11-07

RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CD86, FELINE CD28, OR FELINE CTLA-4 AND USES THEREOF

 #87
20130266608
2013-10-10

Methods and compositions to produce vaccines against smallpox in plants

 #88
20130136768
2013-05-30

Recombinant HCMV and RHCMV vectors and uses thereof

 #89
20130022632
2013-01-24

Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

 #90
20130004525
2013-01-03

Inactivating pathogens with oxidizing agents for vaccine production

 #91
20120328653
2012-12-27

Modified immunization vectors

 #92
20120076812
2012-03-29

Antiviral vaccines with improved cellular immunogenicity

 #93
20120070464
2012-03-22

MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES

 #94
20120009654
2012-01-12

MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES

 #95
20120009217
2012-01-12

MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES

 #96
20110217772
2011-09-08

Animal protein free media for cultivation of cells

 #97
20110212131
2011-09-01

METHOD FOR ENHANCING AN IMMUNE RESPONSE

 #98
20110081368
2011-04-07

Protein vaccines against poxviruses

 #99
20110064754
2011-03-17

Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines

 #100
20110038870
2011-02-17

Compositions and methods to enhance the immune system

 #101
20110020908
2011-01-27

Monoparamunity inducers based on attenuated rabbit myxoma viruses

 #102
20110014234
2011-01-20

Methods of preparing myxomavirus compositions

 #103
20100316671
2010-12-16

Monoparamunity inducers based on attenuated rabbit myxomaviruses

 #104
20100310602
2010-12-09

Synthetic glucopyranosyl lipid adjuvants

 #105
20100303894
2010-12-02

treatment

 #106
20100255029
2010-10-07

Newcastle disease virus vectored avian vaccines

 #107
20100196491
2010-08-05

Protein vaccines against poxviruses

 #108
20100183672
2010-07-22

Process for preparing live smallpox vaccine

 #109
20100028383
2010-02-04

Chemically defined vaccine stabiliser

 #110
20090087451
2009-04-02

Methods and compositions for vaccination

 #111
20080267920
2008-10-30

Monoparamunity inducers based on attenuated rabbit myxomaviruses

 #112
20080213307
2008-09-04

Monoparamunity inducers based on attenuated rabbit myxomaviruses

 #113
20080145382
2008-06-19

RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CD86, FELINE CD28, OR FELINE CTLA-4 AND USES THEREOF

 #114
20080112978
2008-05-15

Method for treatment of HIV infection

 #115
20080044377
2008-02-21

Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine

 #116
20070237790
2007-10-11

Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes

 #117
20070154455
2007-07-05

Paramunity inducers based on attenuated rabbit myxoma virus

 #118
20070031451
2007-02-08

Inactivating pathogens with oxidizing agents for vaccine production

 #119
20070031450
2007-02-08

Stabilizers for veterinary vaccines

 #120
20060134646
2006-06-22

Method for treatment of HIV infection

 #121
20060093620
2006-05-04

Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods

 #122
20050208020
2005-09-22

Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines

 #123
20050025747
2005-02-03

Vaccine

 #124
20050019349
2005-01-27

Poxvirus containing formulations and process for preparing stable poxvirus containing compositions

 #125
19026296
2025-06-10

mRNA vaccine encoding fusion antigen against Mpox and severe acute respiratory syndrome coronavirus 2